<DOC>
	<DOCNO>NCT02831855</DOCNO>
	<brief_summary>This study design evaluate efficacy safety tofacitinib modify release formulation ( 11mg QD ) versus tofacitinib modify release formulation plus continued methotrexate treatment subject moderate severe rheumatoid arthritis insufficiently respond stable dose methotrexate treatment .</brief_summary>
	<brief_title>Methotrexate Withdrawal Study Tofacitinib Modified Release Formulation Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Key Inclusion Criteria Must 18 year age old . Have score 6 great 2010 American College Rheumatology/European League Against Rheumatism Classification Criteria Rheumatoid Arthritis and/or prior Screening Visit . Have ≥4 tender/painful joint motion ≥4 swollen joint ( 28 joint count ) Screening Visit Baseline Visit ( Visit 1 ) . Have moderate severe disease activity define CDAI &gt; 10 DAS284 ( ESR ) ≥3.2 Baseline Visit . Have take oral MTX treatment regimen ( 1525mg/week ) continuously least 4 month prior screen visit take stable weekly dose oral MTX supplemental folic acid folinic acid least 4 week prior baseline visit ( conversion parenteral MTX oral MTX require stabilization treatment regimen least 1 month ) . Subjects must screen negative active tuberculosis inadequately treat tuberculosis infection ( active latent ) . Key Exclusion Criteria Pregnant female subject ; breastfeed female subject ; male subject partner currently pregnant ; male subject able father child female subject childbearing potential unwilling unable use 2 highly effective method contraception outline protocol duration study least 3 month last dose investigational product . Subjects infection infection history ; subject current malignancy history malignancy ( except adequately treat excised nonmetastatic basal cell squamous cell cancer skin cervical carcinoma situ ) ; subject history , current evidence , severe gastrointestinal narrowing ( pathologic iatrogenic ) ; subject history document diverticulitis . Subjects history insufficient response ≥2 biologics , regardless class .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>methotrexate withdrawal</keyword>
	<keyword>withdrawal study</keyword>
</DOC>